$1.35 Billion is the total value of Cormorant Asset Management, LP's 58 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 200.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $94,875,000 | +5.0% | 4,312,498 | +5.5% | 7.02% | +4.2% |
| NKTR | Buy | NEKTAR THERAPEUTICScall | $89,281,000 | -45.1% | 1,828,400 | +19.4% | 6.61% | -45.5% |
| ANAB | Buy | ANAPTYSBIO INC | $87,622,000 | -23.7% | 1,233,422 | +11.7% | 6.48% | -24.3% |
| IFRX | Buy | INFLARX NV | $47,964,000 | +18.9% | 1,487,265 | +6.3% | 3.55% | +18.0% |
| AVRO | New | AVROBIO INC | $43,062,000 | – | 1,507,783 | +100.0% | 3.19% | – |
| AUTL | New | AUTOLUS THERAPEUTICS PLCspon ads | $40,870,000 | – | 1,525,587 | +100.0% | 3.02% | – |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $34,914,000 | -11.9% | 550,000 | +27.3% | 2.58% | -12.5% |
| TCDA | New | TRICIDA INC | $27,944,000 | – | 934,588 | +100.0% | 2.07% | – |
| KZR | New | KEZAR LIFE SCIENCES INC | $27,211,000 | – | 1,572,910 | +100.0% | 2.01% | – |
| SPPI | New | SPECTRUM PHARMACEUTICALS INC | $25,152,000 | – | 1,200,000 | +100.0% | 1.86% | – |
| TSRO | Buy | TESARO INC | $24,459,000 | +22.3% | 550,000 | +57.1% | 1.81% | +21.4% |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $19,620,000 | +297.3% | 450,000 | +260.0% | 1.45% | +294.6% |
| New | OMEROS CORPcall | $17,578,000 | – | 969,000 | +100.0% | 1.30% | – | |
| KNSA | New | KINIKSA PHARMACEUTICALS LTD | $13,842,000 | – | 831,000 | +100.0% | 1.02% | – |
| INCY | New | INCYTE CORP | $13,400,000 | – | 200,000 | +100.0% | 0.99% | – |
| INSP | New | INSPIRE MED SYS INC | $11,590,000 | – | 325,000 | +100.0% | 0.86% | – |
| EIDX | New | EIDOS THERAPEUTICS INC | $7,455,000 | – | 385,846 | +100.0% | 0.55% | – |
| TBIO | New | TRANSLATE BIO INC | $5,750,000 | – | 454,550 | +100.0% | 0.42% | – |
| ITRM | New | ITERUM THERAPEUTICS PLC | $5,445,000 | – | 500,000 | +100.0% | 0.40% | – |
| SRRK | New | SCHOLAR ROCK HOLDING CORP | $3,277,000 | – | 210,078 | +100.0% | 0.24% | – |
| MGTX | New | MEIRAGTX HOLDINGS PLC | $2,734,000 | – | 238,580 | +100.0% | 0.20% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-13 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.